D
Daniel C. Gray
Researcher at University of California, San Francisco
Publications - 18
Citations - 2129
Daniel C. Gray is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Serine/threonine-specific protein kinase & RNA interference. The author has an hindex of 12, co-authored 18 publications receiving 1918 citations. Previous affiliations of Daniel C. Gray include Genentech.
Papers
More filters
Journal ArticleDOI
Sexually dimorphic neurons in the ventromedial hypothalamus govern mating in both sexes and aggression in males.
Cindy F. Yang,Michael C. Chiang,Daniel C. Gray,Mahalakshmi Prabhakaran,Maricruz Alvarado,Scott A. Juntti,Elizabeth K. Unger,James A. Wells,Nirao M. Shah +8 more
TL;DR: It is shown that sexually dimorphic neurons can control distinct sex-typical behaviors in both sexes, and the corresponding ablation in males reduces mating and aggression.
Journal ArticleDOI
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
Michael Degtyarev,Ann De Mazière,Christine Orr,Jie Lin,Brian Lee,Janet Tien,Wei Wei Prior,Suzanne van Dijk,Hong Wu,Daniel C. Gray,David Davis,Howard M. Stern,Lesley J. Murray,Klaus P. Hoeflich,Judith Klumperman,Lori Friedman,Kui Lin +16 more
TL;DR: It is shown that silencing Akt1 alone, or any combination of Akt isoforms, can suppress the growth of tumors established from phosphatase and tensin homologue–null human cancer cells, and suggests that blocking lysosomal degradation can be detrimental to cancer cell survival when autophagy is activated.
Journal ArticleDOI
Inhibitor Hijacking of Akt Activation
Tatsuya Okuzumi,Dorothea Fiedler,Chao Zhang,Daniel C. Gray,Brian Aizenstein,Randy Hoffman,Kevan M. Shokat,Kevan M. Shokat +7 more
TL;DR: It is concluded that ATP-competitive Akt inhibitors impart regulatory phosphorylation of their target kinase Akt providing new insights into both natural regulation of Akt activation andAkt inhibitors entering the clinic.
Journal ArticleDOI
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Klaus P. Hoeflich,Daniel C. Gray,Michael Eby,Janet Tien,Leo Wong,Janeko Bower,Alvin Gogineni,Jiping Zha,Mary J. Cole,Howard M. Stern,Lesley J. Murray,David Davis,Somasekar Seshagiri +12 more
TL;DR: Inducible short-hairpin RNA xenograft models are developed to examine the in vivo efficacy of inhibiting oncogenic BRAF and show that tumor regression resulting from BRAF suppression is inducible, reversible, and tightly regulated in these models.
Journal ArticleDOI
Activation of Specific Apoptotic Caspases with an Engineered Small Molecule-Activated Protease
TL;DR: A model of proteolytic reciprocal negative regulation with mechanistic implications for the combined clinical use of proteasome inhibitors and proapoptotic drugs is proposed.